Do analysts rate INM or EGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is INM or EGRX more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat InMed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets InMed Pharmaceuticals N/A -156.08% -123.90% Eagle Pharmaceuticals N/A N/A N/A

Does the media refer more to INM or EGRX?

In the previous week, InMed Pharmaceuticals and InMed Pharmaceuticals both had 1 articles in the media. InMed Pharmaceuticals' average media sentiment score of 0.73 beat Eagle Pharmaceuticals' score of 0.48 indicating that InMed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eagle Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CYCN or INM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to CYCN or INM?

In the previous week, Cyclerion Therapeutics and Cyclerion Therapeutics both had 1 articles in the media. InMed Pharmaceuticals' average media sentiment score of 0.73 beat Cyclerion Therapeutics' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cyclerion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InMed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CTXR or INM more profitable?

Citius Pharmaceuticals' return on equity of -59.57% beat InMed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -59.57% -34.47% InMed Pharmaceuticals N/A -156.08% -123.90%

Does the media prefer CTXR or INM?

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 1 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.73 beat Citius Pharmaceuticals' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InMed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate INM or MBRX?

Moleculin Biotech has a consensus price target of $3.00, suggesting a potential upside of 451.47%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better earnings and valuation, INM or MBRX?

InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMed Pharmaceuticals N/A N/A -$12.56M -$1.64 N/A Moleculin Biotech N/A N/A -$33.56M -$7.13 N/A

Is INM or MBRX more profitable?

Moleculin Biotech's return on equity of -143.51% beat InMed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets InMed Pharmaceuticals N/A -156.08% -123.90% Moleculin Biotech N/A -143.51% -24.53%

Does the media favor INM or MBRX?

In the previous week, Moleculin Biotech had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 2 mentions for Moleculin Biotech and 1 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.73 beat Moleculin Biotech's score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PSTV or INM?

Plus Therapeutics currently has a consensus price target of $51.75, indicating a potential upside of 2,553.85%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Plus Therapeutics is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, PSTV or INM?

Plus Therapeutics is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A InMed Pharmaceuticals N/A N/A -$12.56M -$1.64 N/A

Does the media refer more to PSTV or INM?

In the previous week, Plus Therapeutics and Plus Therapeutics both had 1 articles in the media. InMed Pharmaceuticals' average media sentiment score of 0.73 beat Plus Therapeutics' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InMed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

InMed Pharmaceuticals (INM) Competitors

$1.38 -0.01 (-0.72%)

As of 11:37 AM Eastern

Compare

INM vs. EGRX, CYCN, CTXR, MBRX, and PSTV

Should you buy InMed Pharmaceuticals stock or one of its competitors? InMed Pharmaceuticals's main competitors and comparable companies include Eagle Pharmaceuticals (EGRX), Cyclerion Therapeutics (CYCN), Citius Pharmaceuticals (CTXR), Moleculin Biotech (MBRX), and Plus Therapeutics (PSTV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does InMed Pharmaceuticals compare to Eagle Pharmaceuticals?

InMed Pharmaceuticals (NASDAQ:INM) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Eagle Pharmaceuticals has higher revenue and earnings than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	N/A	N/A	-$12.56M	-$1.64	N/A
Eagle Pharmaceuticals	$257.55M	0.05	$35.64M	$1.18	0.76

In the previous week, InMed Pharmaceuticals and InMed Pharmaceuticals both had 1 articles in the media. InMed Pharmaceuticals' average media sentiment score of 0.73 beat Eagle Pharmaceuticals' score of 0.48 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eagle Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InMed Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Eagle Pharmaceuticals' return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	N/A	-156.08%	-123.90%
Eagle Pharmaceuticals	N/A	N/A	N/A

Summary

Eagle Pharmaceuticals beats InMed Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Cyclerion Therapeutics?

Cyclerion Therapeutics (NASDAQ:CYCN) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Cyclerion Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

In the previous week, Cyclerion Therapeutics and Cyclerion Therapeutics both had 1 articles in the media. InMed Pharmaceuticals' average media sentiment score of 0.73 beat Cyclerion Therapeutics' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cyclerion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InMed Pharmaceuticals has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -87.96% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%
InMed Pharmaceuticals	N/A	-156.08%	-123.90%

Cyclerion Therapeutics has higher revenue and earnings than InMed Pharmaceuticals. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclerion Therapeutics	$2.07M	7.89	-$3.53M	-$1.66	N/A
InMed Pharmaceuticals	N/A	N/A	-$12.56M	-$1.64	N/A

Summary

Cyclerion Therapeutics beats InMed Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 5.0% of Citius Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Citius Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 786.52%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Citius Pharmaceuticals is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InMed Pharmaceuticals has lower revenue, but higher earnings than Citius Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	$7.11M	2.18	-$37.43M	-$1.67	N/A
InMed Pharmaceuticals	N/A	N/A	-$12.56M	-$1.64	N/A

Citius Pharmaceuticals' return on equity of -59.57% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-59.57%	-34.47%
InMed Pharmaceuticals	N/A	-156.08%	-123.90%

Citius Pharmaceuticals has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, InMed Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 1 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.73 beat Citius Pharmaceuticals' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Citius Pharmaceuticals beats InMed Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Moleculin Biotech?

InMed Pharmaceuticals (NASDAQ:INM) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by insiders. Comparatively, 18.0% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	N/A	N/A	-$12.56M	-$1.64	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

In the previous week, Moleculin Biotech had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 2 mentions for Moleculin Biotech and 1 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.73 beat Moleculin Biotech's score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InMed Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

Moleculin Biotech has a consensus price target of $3.00, suggesting a potential upside of 451.47%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Moleculin Biotech's return on equity of -143.51% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	N/A	-156.08%	-123.90%
Moleculin Biotech	N/A	-143.51%	-24.53%

Summary

Moleculin Biotech beats InMed Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Plus Therapeutics is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
InMed Pharmaceuticals	N/A	N/A	-$12.56M	-$1.64	N/A

Plus Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Plus Therapeutics currently has a consensus price target of $51.75, indicating a potential upside of 2,553.85%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Plus Therapeutics is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Plus Therapeutics and Plus Therapeutics both had 1 articles in the media. InMed Pharmaceuticals' average media sentiment score of 0.73 beat Plus Therapeutics' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

InMed Pharmaceuticals has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. InMed Pharmaceuticals' return on equity of -156.08% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
InMed Pharmaceuticals	N/A	-156.08%	-123.90%

Summary

InMed Pharmaceuticals beats Plus Therapeutics on 7 of the 13 factors compared between the two stocks.

Get InMed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INM vs. The Competition

Export

Metric	InMed Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.57M	$12.59B	$7.27B	$13.03B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-0.84	797.34	274.95	25.63
Price / Sales	N/A	850.56	669.16	97.27
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	4.31	10.60	10.32	6.26
Net Income	-$12.56M	$2.84B	$3.49B	$360.12M
7 Day Performance	-0.72%	-0.98%	-1.33%	-0.42%
1 Month Performance	-3.50%	-1.77%	-3.71%	-3.75%
1 Year Performance	-36.70%	1.66%	14.41%	4.84%

InMed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INM InMed Pharmaceuticals	1.5155 of 5 stars	$1.38 -0.7%	N/A	-35.5%	$4.57M	N/A	N/A	6
EGRX Eagle Pharmaceuticals	N/A	$1.29 flat	N/A	-73.3%	$16.69M	$257.55M	1.09	100	Gap Down
CYCN Cyclerion Therapeutics	0.7772 of 5 stars	$3.49 +3.9%	N/A	-83.5%	$16.33M	$2.07M	N/A	30	Gap Up High Trading Volume
CTXR Citius Pharmaceuticals	1.8125 of 5 stars	$0.57 +1.4%	$5.00 +780.3%	-50.6%	$15.59M	N/A	N/A	20	Analyst Forecast
MBRX Moleculin Biotech	3.0936 of 5 stars	$0.73 -2.7%	$3.00 +310.4%	-95.1%	$14.61M	N/A	N/A	20	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INM) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InMed Pharmaceuticals (INM) Competitors

INM vs. EGRX, CYCN, CTXR, MBRX, and PSTV

How does InMed Pharmaceuticals compare to Eagle Pharmaceuticals?

Summary

How does InMed Pharmaceuticals compare to Cyclerion Therapeutics?

Summary

How does InMed Pharmaceuticals compare to Citius Pharmaceuticals?

Summary

How does InMed Pharmaceuticals compare to Moleculin Biotech?

Summary

How does InMed Pharmaceuticals compare to Plus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InMed Pharmaceuticals (INM) Competitors

INM vs. EGRX, CYCN, CTXR, MBRX, and PSTV

How does InMed Pharmaceuticals compare to Eagle Pharmaceuticals?

Which has better earnings & valuation, INM or EGRX?

Does the media refer more to INM or EGRX?

Which has more risk & volatility, INM or EGRX?

Do analysts rate INM or EGRX?

Do insiders and institutionals hold more shares of INM or EGRX?

Is INM or EGRX more profitable?

Summary

How does InMed Pharmaceuticals compare to Cyclerion Therapeutics?

Which has more risk and volatility, CYCN or INM?

Does the media refer more to CYCN or INM?

Do institutionals and insiders believe in CYCN or INM?

Do analysts rate CYCN or INM?

Is CYCN or INM more profitable?

Which has preferable valuation and earnings, CYCN or INM?

Summary

How does InMed Pharmaceuticals compare to Citius Pharmaceuticals?

Do insiders & institutionals hold more shares of CTXR or INM?

Do analysts recommend CTXR or INM?

Which has higher earnings & valuation, CTXR or INM?

Is CTXR or INM more profitable?

Which has more volatility & risk, CTXR or INM?

Does the media prefer CTXR or INM?

Summary

How does InMed Pharmaceuticals compare to Moleculin Biotech?

Do institutionals & insiders have more ownership in INM or MBRX?

Which has better earnings and valuation, INM or MBRX?

Does the media favor INM or MBRX?

Which has more volatility & risk, INM or MBRX?

Do analysts rate INM or MBRX?

Is INM or MBRX more profitable?

Summary

How does InMed Pharmaceuticals compare to Plus Therapeutics?

Which has stronger valuation and earnings, PSTV or INM?

Which has more volatility and risk, PSTV or INM?

Do analysts rate PSTV or INM?

Does the media refer more to PSTV or INM?

Do institutionals and insiders believe in PSTV or INM?

Is PSTV or INM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools